Dysphoric milk ejection reflex sense of depression and this feeling can range from mild homesickness or wistfulness to more intense feelings of hopelessness and self-loathing. Similarly, anxiety may range from restlessness to more intense panic and dread. Anger, the least likely of the three, may range from tension and agitation to more intense feelings of hostility and aggression. The mechanism is not clear. In a mother with D-MER, dopamine may fall inappropriately with milk release, causing the negative feelings. Among the hormones involved in milk production and release are oxytocin, prolactin, and dopamine. Oxytocin, released in pulsatile "spikes" from the posterior pituitary in response
Cabazitaxel mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). Cabazitaxel Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy. Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment. In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival